RxDoctor Payments Data

Mayer Hasbani, MD

Clinical Neurophysiology · New Haven, CTNPI 1780632968

Payments from drug & device makers

$1,283,556in general payments, 2019–2025

Across 3,421 payments — averaging $375.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$412K
  • Ipsen Pharma SAS$211K
  • AbbVie$78K
  • Otsuka America Pharmaceutical, Inc.$74K
  • Teva Pharmaceuticals USA, Inc.$60K
  • Eisai Inc.$57K
  • plus $389K from 54 others

What the payments were for

  • Consulting fees$51,7099%
  • Speaking & faculty fees$421,72072%
  • Grants$880%
  • Travel & lodging$31,6975%
  • Food & beverage$75,50013%
  • Education$1,6850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.11$412,368
Ipsen Pharma SAS68$211,042
AbbVie(2 entities)354$78,151
Otsuka America Pharmaceutical, Inc.97$74,196
Teva Pharmaceuticals USA, Inc.237$59,579
Eisai Inc.124$56,788
Sanofi124$54,074
Acorda Therapeutics, Inc77$45,109
Ipsen Innovation33$43,097
Amgen(2 entities)172$41,342
Biogen185$37,006
Merz Pharmaceuticals, LLC7$35,152
Lilly USA, LLC85$31,306
Avanir Pharmaceuticals, Inc.58$29,254
Kyowa Kirin, Inc.60$14,009
EMD Serono, Inc.203$6,493
Genentech USA, Inc.62$6,297
Acadia Pharmaceuticals Inc20$5,172
MDD US Operations, LLC60$4,687
Sanofi-aventis U.S. LLC3$3,602
Novartis121$3,312
SK Life Science, Inc.124$2,609
Amneal Pharmaceuticals LLC139$2,546
Medtronic(3 entities)23$2,273
Lundbeck LLC87$2,098
UCB, Inc.67$1,547
Supernus Pharmaceuticals, Inc.89$1,300
Argenx US, Inc.24$1,283
Neurocrine Biosciences, Inc.47$1,248
Mallinckrodt Hospital Products Inc.35$1,097
Johnson & Johnson(2 entities)32$1,045
Pfizer53$912
TG Therapeutics, Inc.25$839
AstraZeneca(2 entities)24$768
Avadel CNS Pharmaceuticals, LLC43$753
Adamas Pharmaceuticals, Inc.54$730
Alnylam Pharmaceuticals Inc.18$601
CSL Behring23$598
Bristol Myers Squibb35$594
Neurelis, Inc.14$534
Grifols USA, LLC20$510
Genentech, Inc.5$498
Akcea Therapeutics, Inc.13$491
Axsome Therapeutics, Inc.12$431
Upsher-smith Laboratories LLC12$393
Biohaven Pharmaceuticals, Inc.11$387
Jazz Pharmaceuticals Inc.8$377
Abbott6$310
Assertio Therapeutics, Inc.31$299
Alkermes, Inc.12$284
Sunovion Pharmaceuticals Inc.18$270
Vanda Pharmaceuticals Inc.10$270
Takeda Pharmaceuticals U.S.A., Inc.11$249
Sumitomo Pharma America, Inc.8$233
Biohaven Pharmaceutical Holding Company Ltd.9$216
Amylyx Pharmaceuticals, Inc.5$206
Almatica Pharma LLC10$192
Promius Pharma LLC6$177
ANI Pharmaceuticals, Inc.3$175
Arbor Pharmaceuticals, Inc.9$165

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,522,451
Medicare patients
588
Services billed
34,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4617$393,961
AustedoDeutetrabenazine56$391,841
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$216,039
NuplazidPimavanserin Tartrate30$157,563
BotoxOnabotulinumtoxina75$90,430
QuliptaAtogepant56$58,542
Glatiramer Acetate13$57,249
Aimovig AutoinjectorErenumab-Aooe52$49,864
Lamictal XrLamotrigine24$43,623
XcopriCenobamate34$41,061
RytaryCarbidopa/Levodopa23$39,783
RexultiBrexpiprazole23$33,991
Nurtec OdtRimegepant Sulfate21$30,945
Rasagiline Mesylate198$28,790
BriviactBrivaracetam22$28,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$59,579$391,84156 claims
Grifols USA, LLCGamunex-C$510$216,03913 claims
Acadia Pharmaceuticals IncNuplazid$5,172$157,56330 claims
AbbVieBotox, Qulipta, Linzess$78,151$154,828142 claims
PfizerNurtec Odt, Lyrica$912$49,34443 claims
SK Life Science, Inc.Xcopri$2,609$41,06134 claims
Amneal Pharmaceuticals LLCRytary$2,546$39,78323 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74,196$33,99123 claims
UCB, Inc.Briviact$1,547$28,13322 claims
Eisai Inc.Fycompa$56,788$22,91518 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29,254$20,72913 claims
Neurocrine Biosciences, Inc.Ongentys$1,248$8,57613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in New Haven

Where these figures come from

Is this you, or does something look wrong? →